PALI
NASDAQ · Biotechnology
Palisade Bio Inc
$2.12
-0.03 (-1.40%)
Open$2.14
Previous Close$2.15
Day High$2.15
Day Low$2.09
52W High$2.86
52W Low$0.53
Volume—
Avg Volume1.56M
Market Cap368.58M
P/E Ratio—
EPS$-1.17
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+107.5% upside
Current
$2.12
$2.12
Target
$4.40
$4.40
$2.36
$4.40 avg
$4.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.39M | 123.33M | 94.21M |
| Net Income | 12.19M | 12.43M | 9.10M |
| Profit Margin | 10.5% | 10.1% | 9.7% |
| EBITDA | 16.58M | 20.40M | 14.08M |
| Free Cash Flow | 11.50M | 12.12M | 8.26M |
| Rev Growth | -3.2% | +20.3% | +7.0% |
| Debt/Equity | 0.59 | 0.58 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |